TGFB1 and neoplasm: Recently, CSC-targeted DC vaccines have been reported to enhance the elimination of melanoma CSCs in a mouse tumor model with a combination of PD-L1 and CTLA-4 blockades, with an enhanced CD8+ T cell response, increased IFN-γ and inhibited TGF-β expression (Zheng et al., 2018).